OnKure Therapeutics, Inc. Class A Common Stock

Day range

$2.38 – $2.63

Open

$2.59

Prev close

$2.52

Volume

258.09K

Market cap

$102.05M

Shares out

40.4M

P/E

—

P/S

—

P/B

0.59

P/FCF

—

ROE

-34.1%

ROA

-32.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeAug 13, 2026

  On August 7, 2026, the Board of Directors approved an option repricing. The repricing generally applied to all outstanding and unexercised stock options to purchase shares of the Company's Class A common stock granted prior to January 1, 2025, under the Company's 2024 Equity Incentive Plan or the Company's 2021 Stock Incentive Plan, with an exercise price per Share equal to or greater than $10.00, held by certain employees and consultants, including each of the Company's named executive officers.

• Equity compensation grantJun 4, 2026

  OnKure Therapeutics, Inc. (the "Company") amended and restated its 2024 Equity Incentive Plan (the "A&R 2024 Plan"), effective as of June 3, 2026 upon approval by the stockholders of the Company at the Annual Meeting. The amendments to the Company's 2024 Equity Incentive Plan included (1) a one-time increase to the number of shares of common stock reserved for issuance by approximately 8% of the Company's outstanding shares (3,231,638 shares), (2) an amendment to the annual "evergreen" provision to remove the annual limit of 2,407,100 shares while maintaining the annual increase at 5% of the Company's outstanding shares.

• Private placementMar 30, 2026

  the Company agreed to issue and sell to the Investors in a private placement (i) 26,713,636 shares of the Company's Class A common stock at a purchase price of $4.15 per Share, and (ii) pre-funded warrants to purchase 9,430,959 shares of Common Stock at a purchase price of $4.1499 per underlying Warrant Share. The aggregate gross proceeds from the Private Placement are expected to be approximately $150.0 million.

• Underwriting agreementNov 6, 2025

  The Sales Agreement provides that Leerink Partners will be entitled to compensation for its services of up to 3.0% of the gross proceeds from the sales of Placement Shares through Leerink Partners under the Sales Agreement. Leerink Partners has agreed to use commercially reasonable efforts consistent with its normal trading and sales practices to sell such Placement Shares.

• Business updateNov 6, 2025

  Press Release titled 'OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update' dated November 6, 2025.

Days to cover

4.8

Short interest

1.22M

Avg volume

257.07K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
  positiveGlobeNewswire Inc.· Aug 31, 2026
• OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
  positiveGlobeNewswire Inc.· Jul 2, 2026
• OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
  positiveGlobeNewswire Inc.· Dec 10, 2024